BDBM228181 2-(3-tert-Butyl-[1,2,4]triazol-1-yl)-1-{(R)-2-methyl-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl}-ethanone::US10047080, 8::US9328099, 40-22::US9328099, 40-6

SMILES CC1CNCC(N1C(=O)Cn1cnc(n1)C(C)(C)C)c1sc(cc1-c1cnc(nc1)C(F)(F)F)C(F)(F)F

InChI Key InChIKey=YJXYPYNJOJGYQR-UHFFFAOYSA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 228181   

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM228181(2-(3-tert-Butyl-[1,2,4]triazol-1-yl)-1-{(R)-2-meth...)
Affinity DataIC50: 1.60nMpH: 7.4Assay Description:The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered CHO-K1 cells expressing the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/10/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM228181(2-(3-tert-Butyl-[1,2,4]triazol-1-yl)-1-{(R)-2-meth...)
Affinity DataIC50: 4nMT: 2°CAssay Description:The reactions employed a common peptide substrate, LCB-EQEDEPEGDYFEWLW-NH2 (in-house). The basic assay protocol is as follows: First, 250 nL of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/18/2017
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM228181(2-(3-tert-Butyl-[1,2,4]triazol-1-yl)-1-{(R)-2-meth...)
Affinity DataIC50: 12nMT: 2°CAssay Description:The reactions employed a common peptide substrate, LCB-EQEDEPEGDYFEWLW-NH2 (in-house). The basic assay protocol is as follows: First, 250 nL of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/18/2017
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM228181(2-(3-tert-Butyl-[1,2,4]triazol-1-yl)-1-{(R)-2-meth...)
Affinity DataIC50: 195nMT: 2°CAssay Description:The reactions employed a common peptide substrate, LCB-EQEDEPEGDYFEWLW-NH2 (in-house). The basic assay protocol is as follows: First, 250 nL of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/18/2017
Entry Details
US Patent

TargetC-X-C chemokine receptor type 3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM228181(2-(3-tert-Butyl-[1,2,4]triazol-1-yl)-1-{(R)-2-meth...)
Affinity DataIC50: 349nMAssay Description:Stock solutions of test compounds are made up at a concentration of 10 mM in DMSO, and serially diluted in PBS containing 0.5% BSA to concentrations ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/10/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM228181(2-(3-tert-Butyl-[1,2,4]triazol-1-yl)-1-{(R)-2-meth...)
Affinity DataIC50: 365nMT: 2°CAssay Description:The reactions employed a common peptide substrate, LCB-EQEDEPEGDYFEWLW-NH2 (in-house). The basic assay protocol is as follows: First, 250 nL of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/18/2017
Entry Details
US Patent